Two-year data from the European multicentre tacrolimus (FK 506) liver study

Transplant International

Volumn 9, Issue SUPPL. 1, 1996, Pages

  Williams, Roger ^a   Neuhaus, Peter ^b   Bismuth, Henri ^c   McMaster, Paul ^d   Pichlmayr, Rudolf ^e   Calne, Roy ^f   Otto, Gerd ^g   Groth, Carl ^h  

^a KING S COLLEGE HOSPITAL   (United Kingdom)

^b HUMBOLDT UNIVERSITY   (Germany)

^c HÔPITAL PAUL BROUSSE   (France)

^d QUEEN ELIZABETH HOSPITAL   (United Kingdom)

^e HANNOVER MEDICAL SCHOOL   (Germany)

^f ADDENBROOKE S HOSPITAL   (United Kingdom)

^g UNIVERSITY OF HEIDELBERG   (Germany)

^h KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

Author keywords

Comparative study; Cyclosporin; Immunosuppressive treatment failure; Primary liver transplantation; Tacrolimus

Indexed keywords

AZATHIOPRINE; CYCLOSPORIN; IMMUNOSUPPRESSIVE AGENT; STEROID; TACROLIMUS;

ADOLESCENT; ADULT; AGED; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG EFFICACY; DRUG SAFETY; FEMALE; GINGIVA HYPERPLASIA; GLUCOSE METABOLISM; GRAFT REJECTION; GRAFT SURVIVAL; HIRSUTISM; HUMAN; HYPERTENSION; IMMUNOSUPPRESSIVE TREATMENT; MAJOR CLINICAL STUDY; MALE; METABOLIC DISORDER; MULTICENTER STUDY; NEPHROTOXICITY; NEUROTOXICITY; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SURVIVAL;

EID: 0029979866     PISSN: 09340874     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1432-2277.1996.tb01592.x     Document Type: Article

References (17)

1. Bismuth H for the European FK506 multicenter liver study group (1995) Comparison of FK 506- and cyclosporine-based immunosuppression: FK506 therapy significantly reduces the incidence of acute, steroid-resistant, refractory, and chronic rejection whilst possessing a comparable safety profile. Transplant Proc 27:45-49
2. Bismuth H, Samuel D, Neuhaus P, McMaster P, Calne R, Pichlmayr R, Otto G, Williams R, Groth C (1994) Focus on intractable rejection: 6-month results of the European multicentre study of FK 506 and cyclosporin A. Transplant Int 7 [Suppl 1]: S3-S6
3. Christe W (1994) Neurological disorders in liver and kidney transplant recipients. Transplant Proc 26:3175-3176
4. Devlin J, Williams R, Neuhaus P, McMaster P, Calne R, Pichlmayr R, Otto G, Bismuth H, Groth C (1994) Renal complications and development of hypertension in the European study of FK506 and cyclosporin in primary liver transplant recipients. Transplant Int 7 [Suppl 1]: S22-S26
5. Ericzon B, Groth C. Bismuth H, Calne R, McMaster P, Neuhaus P, Otto G, Pichlmayr R, Williams R (1994) Glucose metabolism in liver transplant recipients treated with FK506 or cyclosporin in the European multicentre study. Transplant Int 7 [Suppl 1]: S11-S14
6. European FK 506 multicentre liver study group (1994) Randomised trial comparing tacrolimus (FK506) and cyclosporin in prevention of liver allograft rejection. Lancet 344: 423-428
7. Frei U, Wagner K (1994) Renal function in liver transplant patients receiving FK 506 or cyclosporin A immunosuppressive therapy. Transplant Proc 26: 3270-3271
8. Fung J, Abu-Elmagd K, Jain A, Gordon R, Tzakis A, Todo S, Takaya S, Alessiani M, Demetris A, Bronster O, Martin M. Mieles L, Selby R, Reyes J, Doyle H, Stieber A, Casavilla A. Starzl T (1991) A randomized trial of primary liver transplantation under immunosuppression with FK 506 vs cyclosporine. Transplant Proc 23: 2977-2983
9. McMaster P (1994) Patient and graft survival in the European multicentre liver study- FK506 vs cyclosporin A. Transplant Int 7 [Suppl 1]: S32-S36
10. Neuhaus PJ (1994) Optimised first-line FK506-based protocol in liver transplantation: experience from the University Hospital Rudolf Virchow, Berlin. Transplant Proc 26: 3264-3266
11. Neuhaus P, McMaster P, Calne R, Pichlmayr R, Otto G, Williams R, Bismuth H, Groth C (1994) Neurological complications in the European multicentre study of FK 506 and cyclosporin in primary liver transplantation. Transplant Int 7 [Suppl 1]: S27-S31
12. Otto G, Bleyl J, Neuhaus P, McMaster P, Calne R, Pichlmayr R, Williams R, Bismuth H, Groth C (1994) Corticosteroids and concomitant medication in the European multicentre study of FK 506 and cyclosporin in primary liver transplantation. Transplant Int 7 [Suppl 1]: S7-S10
13. Starzl TE, Donner A, Eliasziw M, Stitt L, Meier P, Fung JJ, McMichael JP, Todo S (1995) Randomized trialomania? The multicenter liver transplant trials. Lancet 346: 1346-1350
14. The European FK506 multicentre liver study group (1994) Reduced incidence of acute, refractory acute, and chronic rejection after liver transplantation with FK 506-based immunosuppression. Transplant Proc 26: 3260-3263
15. The U.S. multicenter FK506 liver study group (1994) A comparison of tacrolimus (FK 506) and cyclosporine for immunosuppression in liver transplantation. N Engl J Med 331: 1110-1115
16. Todo S, Fung JJ, Tzakis A, Demetris AJ, Jain A, Alessiani M, Takaya S, Day R, Gordon R, Starzl TE (1991) One hundred ten consecutive primary orthotopic liver transplants under FK 506 in adults. Transplant Proc 23: 1397-1402
17. Winkler M, Pichlmayr R, Neuhaus P, McMaster P, Calne R, Otto G, Williams R, Bismuth H, Groth C (1994) Optimal FK 506 dosage in patients under primary immunosuppression following liver transplantation. Transplant Int 7 [Suppl 1]: S58-S63